Explore the Agenda
8:00 am Registration & Coffee
8:50 am Chair’s Opening Remarks
Comparing New TCR‑Based Strategies to Expand Targets & Overcome Resistance
9:00 am Preclinical Characterization of CBX‑663, a First‑in‑Class TCR Mimetic T‑Cell Engager Targeting TERT for Solid & Hematologic Malignancies
- Rationale for Crossbow Therapeutics’ approach to TERT targeting and for CBX-663 design
- In vitro binding and in vitro potency against cancer cell lines, demonstrating superior potency of bivalent vs. monovalent format (2+1 vs 1+1)
- In vivo efficacy in mouse CDX models of AML and NSCLC, and in vitro and in vivo safety with focus on bone marrow progenitor cells
9:30 am Activating T-Cells Through Novel TCR-Based Platforms to Overcome Resistance in Solid Tumors
- Introducing the first-in-class STAR platform that selectively activates T-cells via the variable beta chain
- Demonstrating feasibility and safety of this novel mechanism with encouraging preliminary clinical data
- Achieving pan-tumor activity across seven solid tumor types, and HLA-agnostic TCR activation to broaden patient access and redefine therapeutic strategies
10:00 am Session Reserved for Adimab
10:30 am Morning Break & Networking
Leveraging Novel Techniques to Exploit Resistance Mechanisms & Broaden Patient Impact
11:00 am Expanding Therapeutic Possibilities Pursuing pMHC Targets Beyond Convention
- Antigen-guided TCE development
- Targeting haptenated peptides as a way of breaking HLA restriction
- Exploiting resistance mechanisms to cancer treatments that unlock new targets for immunotherapies
12:00 pm Session Reserved for Miltenyi Biotec
12:30 pm Lunch Break & Networking
Streamlining Manufacturing to Improve Cost Efficiency & Accelerating Progress into the Clinic
1:30 pm Bringing a Next-Generation Autologous TCR-T-Cell Therapy into the Clinic for Triple Negative Breast Cancer
- Introducing a first-in-class TCR engineered therapy against a novel target expressed in over 90 percent of triple negative breast cancer and melanoma patients
- Demonstrating how built in co-stimulatory domains within the TCR can enhance T-cell durability while maintaining a compact engineering payload relevant for future in vivo delivery
- Translating promising preclinical data into a cost-effective and scalable clinical manufacturing strategy to unlock cell therapy for hard-to-treat solid tumors
2:00 pm From Custom to On-Demand: Making TCR-Based Cell Therapies Commercially Scalable
- Changing the paradigm, from autologous to allogeneic, from single antigen to multiple activation mechanisms, from custom to on-demand
- Current opportunities and challenges of large-scale TCR-NK cells manufacturing
- Approaches to tackle cost-of-goods and increase patient access
2:30 pm Afternoon Break & Networking
Advancing TCR Therapies from Discovery to Clinical Translation & Commercial Success
3:30 pm Translating TCR-Based Cell Therapies into the Clinic
- Enabling technologies for allogeneic TCR-engineered Treg therapies for autoimmune disease
- Safety considerations and risk-mitigation approaches for an allogeneic TCR therapies for autoimmune disease
- Regulatory strategy and IND-enabling experience for autologous TCR-based cell therapy programs
4:00 pm Guiding TCR Therapies from Discovery to Dosing Using End-to-End Platform Insights
- Conducting MABEL calculations and safety studies in organoids to guide dosing
- Characterizing clinical performance early to strengthen development decisions
- Leveraging the end-to-end benefits of a target discovery platform to derisk your product